Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264406 | 0.81 | KDM4E (0.48) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL15693585 | 0.80 | CA12 (0.59) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL455971 | 0.76 | LMNA (0.51) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL9608587 | 0.75 | LMNA (0.50) | LMNAKDM4EALDH1A1CA12CA7 | |
| Hydrochloric Acid SCHEMBL3665461 | 0.75 | LMNA (0.50) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL1768430 | 0.74 | LMNA (0.46) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL1768432 | 0.74 | LMNA (0.46) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL1654774 | 0.73 | LMNA (0.49) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL4274142 | 0.73 | LMNA (0.49) | LMNAKDM4EALDH1A1CA12CA7 | |
| SCHEMBL12521728 | 0.73 | LMNA (0.42) | LMNAKDM4EALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285783-B1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-8546563-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8263597-B2 | Indazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| WO-2009134666-A1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | LMNA 4481/4885KDM4E 3299/4885ALDH1A1 1785/4885 |
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCRL2 | LMNA 4663/4885KDM4E 4244/4885ALDH1A1 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.